|
|
||||||||
J Biol Chem, Vol. 274, Issue 45, 32085-32090, November 5, 1999
From the Molecular Mechanisms of Growth Control Group, Department
of Cell Biology, University of Alberta, Edmonton,
Alberta T6G 2H7, Canada
By using cycling Xenopus egg
extracts, we have previously found that if mitogen-activated protein
kinase (p42 MAPK) is activated on entry into mitosis (M-phase), the
extract is arrested with condensed chromosomes and spindle
microtubules. Here we show that these arrested extracts have high
levels of M-phase promoting factor (MPF, Cyclin B/Cdc2) activity,
stabilized levels of Cyclin B, and sustained M-phase-specific
phosphorylations. We also examined the role of p42 MAPK in DNA damage
checkpoint-arrested extracts that were induced to enter M-phase by the
addition of Cdc25C protein. In these extracts, Cdc25C protein triggers
the abrupt, premature activation of MPF and entry into M-phase. MPF
activity then drops suddenly due to Cyclin B proteolysis, just as p42
MAPK is activated. Unexpectedly, however, M-phase is sustained, as
judged by maintenance of M-phase-specific phosphorylations and
condensed chromosomes. To determine if this M-phase arrest depended on
p42 MAPK activation, we added PD98059 (PD), an inhibitor of p42 MAPK
activation, to egg extracts with exogenous Cdc25. Both untreated and
PD-treated extracts entered M-phase simultaneously, with a sharp peak
of MPF activity. However, only PD-treated extracts subsequently exited from M-phase and entered interphase. In PD-treated extracts, p42 MAPK
was not activated, and the transition to interphase was accompanied by
the formation of decondensed nuclei and the disappearance of M-phase-specific phosphorylation of proteins. These results show that
although entry into M-phase requires the activation of MPF, exit from
M-phase even after cyclin destruction, is dependent on the inactivation
of p42 MAPK.
To date, a large body of research has led to the prevailing view
that M-phase promoting factor
(MPF,1 a complex of cyclin
B/Cdc2) activation is required for entry into M-phase, and its
inactivation is necessary for exit from M-phase (reviewed in Ref. 1).
Studies have shown that p42 mitogen-activated protein kinase (p42 MAPK)
activation maintains high levels of MPF activity and stabilizes Cyclin
B (2-4), leading to the predominant belief that p42 MAPK must sustain
M-phase solely by this mechanism.
We have previously shown that the activation of p42 MAPK in cycling
Xenopus egg extracts by the addition of a constitutively active MAPK kinase (MEK) leads to an arrest of the cell cycle in either
G2- or M-phase, depending on the timing of p42 MAPK activation (5). If p42 MAPK was activated in cycling egg extracts before entry into M-phase, the cell cycle was arrested in
G2 (4-7). If p42 MAPK was activated on entry into M-phase,
however, Cdc25C phosphatase was hyperphosphorylated (5, 7-9), and
nuclear envelope breakdown (NEBD) and chromosome condensation (CC), all markers of M-phase, were sustained (5, 7).
Recently, we and others (7, 10) have shown that activation of p42 MAPK
by Mos can lead to an M-phase arrest that is maintained even after the
inactivation of MPF. We have further shown that MPF levels fall in
these extracts due to mitotic cyclin proteolysis (7). Here, we show
that the inactivation of p42 MAPK is required for exit from an M-phase
arrest that is sustained after mitotic cyclin degradation and Cdc2
inactivation. In the process of initially characterizing recombinant
Cdc25C proteins (wild type and a mutant that cannot be inhibited by
14-3-3 protein binding
(11)2), we have found that
these proteins were able to drive interphase checkpoint-arrested egg
extracts into an M-phase arrest as determined by cytology (NEBD and CC,
see Refs. 11, 12, and this study) and maintenance of M-phase-specific
phosphoproteins (this study).
Unexpectedly, although MPF was activated to high levels on entry into
M-phase in these extracts, Cyclin B was rapidly proteolyzed leading to
an abrupt fall in MPF levels, just as p42 MAPK activity appeared. The
p42 MAPK activation was sustained throughout the M-phase arrest. To
determine the role of p42 MAPK in this M-phase arrest, we added an
inhibitor of MAPK activation to interphase extracts that were then
driven into M-phase by the addition of Cdc25C protein. These extracts
did not show p42 MAPK activation and did not arrest in M-phase.
Instead, after a brief M-phase, the extracts entered interphase.
These results suggest that although the activation of MPF is required
for entry into M-phase, p42 MAPK can sustain M-phase after MPF
inactivation. Moreover, the inactivation of p42 MAPK, rather than MPF,
is required for exit from M-phase.
Preparation of Egg Extracts and Sperm Nuclei--
Cycling
Xenopus egg extracts were prepared as described previously
(5, 13). Briefly, dejellied Xenopus eggs were activated by
electrical shock. At 21-23 min after activation, eggs were packed in
extraction buffer (with protease inhibitors and cytochalasin B), over
silicon oil, and extracts were made by centrifugation twice at
10,200 × g for 15 min at 4 °C. An ATP-regenerating
system was added immediately, and supplemented extracts were kept on ice and used within 1 h.
Egg extracts for DNA damage checkpoint and Cdc25 protein addition
experiments were prepared in the same way, except the extraction buffer
was chilled to 4 °C. Sperm nuclei were prepared as described previously (14) and quantified prior to addition to extracts. For low
sperm addition, preparations were diluted to 14,000 sperm nuclei/µl,
and for high sperm additions, stocks of 49,000 nuclei/µl were
prepared. Extracts of unfertilized eggs that are arrested at metaphase
of meiosis were made as described previously (5) and used as M-phase controls.
Recombinant Protein Preparations--
Constitutively active MEK
protein (MEK(QP)) was expressed as an N-terminal glutathione
S-transferase fusion protein and purified from
Escherichia coli by glutathione-Sepharose affinity
chromatography and then concentrated to 0.8-1.0 mg/ml, as described
previously (5).
Cdc25C protein mutated at amino acid residue 287 (the serine required
for 14-3-3 inhibition (11, 15, 16)) was generated via a two-step
polymerase chain reaction procedure. A BamHI to ClaI fragment of Cdc25C with the Ser-287 to Ala substitution
was generated using two sets of oligonucleotides
(ATGCCAGAGAAGCTTGACAGGCCA and GGATAACGACAATCGATTATAAAG) to introduce an
internal HindIII restriction site, and
ATATAAGCTTCTCTGGCATAGCAGGTGAGCGGTA and GATGAATATCTTGGGATCCCCCAT to introduce the T to C transition, resulting in a Ser to Ala substitution. These two polymerase chain reaction fragments were ligated together and then inserted into pMALCdc25C(wild-type) in which
the internal BamHI to ClaI fragment had been
deleted. Mutant Cdc25C(S287A) protein was expressed as an N-terminal
maltose-binding fusion protein in E. coli and purified by
affinity chromatography using amylose resin according to the
manufacturer's instructions. Protein preparations were concentrated to
0.2 mg/ml.
Assays Using Egg Extracts--
In MEK(QP)-added reactions, 66 µl of supplemented extract was transferred to a 1.5-ml
microcentrifuge tube; 0.5 µl of sperm suspension was added (final
concentration of 100 nuclei/µl), and reactions were incubated in
water baths between 21 and 22 °C. At 0 or 40 min after start of
incubation, 3.5 µl of either buffer or protein was added (to 5%
volume in a final reaction volume of 70 µl), and the reaction was
mixed with wide-bore pipette tips, and initial samples were taken as
described previously for H1 kinase assays, blot analysis, and cytology
(5). Samples were taken every 10 min thereafter.
For DNA damage checkpoint and Cdc25 protein addition experiments,
nuclei were treated with UV irradiation as described previously (11,
12). For these assays, 62 µl of supplemented extract was transferred
to a 1.5-ml microcentrifuge tube; 1.0 µl of sperm nuclei was added
(to a final concentration of 700 sperm nuclei/µl), and 7.0 µl of
maltose binding protein-Cdc25(S287A) protein preparation was added to
achieve a final concentration of 0.16 µM. Reactions were
incubated for 60 min at 21-22 °C before initial samples were taken
for H1 kinase activity assay, blot analysis, and cytology. Samples were
taken every 10 min for up to 120 min. Experiments using the MEK
inhibitor PD98059 (17) (200 µM final concentration, 5)
were performed identically.
Immunoblotting and Histone H1 Kinase Assays--
Immunoblotting
with phosphotyrosine antibodies (18), Cyclin B2, N-terminal antibodies
(19),3, and Cdc25C antibodies
(5) was as described previously (5, 20, 21). MPM-2 antibodies were
obtained from Upstate Biotechnology Inc. Detection of primary antibody
binding was by alkaline phosphatase-conjugated secondary antibody (Sigma).
Histone H1 kinase assays were done exactly as described (5). Because
kinase assays were done with radioisotope of various ages,
32P incorporation into histone H1 is expressed in arbitrary units.
p42 MAPK Activation on Entry into M-phase Arrests the Cell Cycle
with Stabilized MPF and Sustained M-phase-specific
Phosphorylations--
In Fig.
1a, we show that when p42 MAPK
is activated by the addition of a constitutively active MEK (MEK(QP)
(5, 22)) to cycling Xenopus egg extracts on entry into
M-phase, the extract is arrested in M-phase with sustained histone H1
kinase activity, and Cyclin B2 is stabilized in the hyperphosphorylated
form. Nuclear envelope breakdown (NEBD) and chromosome condensation
(CC), markers of M-phase were maintained, with the condensed
chromosomes associated with spindles (Fig. 1b) (5).
These results are similar to those obtained when the spindle assembly
checkpoint and p42 MAPK activation are induced by high concentrations
of nuclei and microtubule depolymerization (2, 23).
In addition to Cdc25C hyperphosphorylation (data not shown) (5), the
extent of the other M-phase-specific phosphorylations in the arrested
extract is shown by the sustained presence of MPM-2-reactive
phosphoproteins, whereas these proteins are detected only transiently
during M-phase in cycling extracts (Fig. 1c). The MPM-2
monoclonal antibody recognizes proteins when they undergo M-phase-specific phosphorylations (7, 24).
Cdc25C Drives Interphase Checkpoint-arrested Egg Extracts into an
M-phase Arrest--
It has been previously shown that egg extracts
containing unreplicated or damaged DNA have an extended interphase and
can be driven into M-phase by the addition of excess recombinant Cdc25C protein (11, 12). In the current study, we observed that egg extracts
with unirradiated sperm nuclei added to 700 sperm/µl cycled slowly
and did not enter M-phase until 140 min of incubation (Fig.
2a), a delay consistent with
previous observations (11, 12, 25).
We then added UV-irradiated sperm nuclei (700 sperm/µl) to cycling
egg extracts to trigger the DNA damage checkpoint in vitro (11, 12). These extracts were arrested in interphase for at least 180 min of incubation, as judged by low levels of histone H1 kinase
activity, interphase nuclei, and lack of MPM-2 reactive phosphoproteins
(Fig. 2b). Hypophosphorylated Cyclin B2 accumulated in these
extracts, similar to the Cyclin B2 accumulation previously observed in
extracts arrested in G2 by MEK(QP) (5).
We purified recombinant epitope-tagged Cdc25C proteins (wild-type (WT)
and a mutant (S287A) in which serine at position 287 has been
substituted with an alanine (11, 12)). When recombinant Cdc25C(S287A)
protein was added to interphase-arrested extracts, the DNA damage
checkpoint was overcome, with the activation of histone H1 kinase
activity inducing entry into M-phase (Fig. 2c) (11, 12). We
observed that the Cdc25C(WT) protein could also rescue the
checkpoint-arrested extracts, but entry into M-phase occurred 20-30
min later than with Cdc25C(S287A) protein (data not shown), as has been
previously reported (11). The S287A mutation abolishes the inhibition
of Cdc25C by 14-3-3 protein binding (11, 15, 16, and data not shown),
which explains why the addition of Cdc25C(S287A) to extracts induces
M-phase earlier than the addition of Cdc25C(WT). However, the fact that
Cdc25C(WT) addition to extracts is also able to induce M-phase suggests
that the total level of Cdc25C (both endogenous and exogenous) exceeds the ability of the extract to inhibit all of the Cdc25C. Both Cdc25C
proteins drive the interphase-arrested extracts into M-phase by
removing the inhibitory tyrosine and threonine phosphorylations on Cdc2
(reviewed in Ref. 26).
The Cdc25(S287A)-rescued extracts were arrested in M-phase, showing
certain features that were similar to those we observed in the
MEK(QP)-induced M-phase-arrested extracts in Fig. 1. In both types of
M-phase-arrested extracts, Cdc25C hyperphosphorylation was maintained
(data not shown), MPM-2-reactive phosphoproteins persisted, and
condensed chromosomes were associated with spindles. In contrast to the
MEK(QP)-induced M-phase-arrested extracts, however, in the
Cdc25C(S287A)-rescued extracts, histone H1 kinase activity dropped
abruptly to interphase levels, and Cyclin B2 was was proteolyzed (Fig.
2c). Interestingly, p42 MAPK was fully activated after the
peak of histone H1 kinase activity in these Cdc25C(S287A)-rescued
extracts (Fig. 2c, 90 min), and p42 MAPK activation was
maintained throughout the M-phase arrest. Thus, in these extracts,
maintenance of M-phase was correlated with sustained p42 MAPK
activation, not high levels of MPF activity or stabilized Cyclin B.
p42 MAPK Inactivation Is Required for Exit from M-phase
Arrest--
To determine if activation of the p42 MAPK pathway was
responsible for the M-phase arrest in egg extracts that had undergone cyclin destruction, the MEK-specific inhibitor, PD98059 (PD (5, 17)),
or vehicle, Me2SO, was added to extracts containing 700 sperm/µl, and then Cdc25C(S287A) was added. As we observed with DNA
damage checkpoint-arrested extracts, Cdc25C(S287A) and
Me2SO addition to egg extracts caused an accelerated entry
into M-phase (data not shown) and subsequent arrest. In this reaction,
the M-phase arrest was accompanied by maintenance of p42 MAPK
activation, MPM-2-reactive phosphoproteins (Fig.
3a), hyperphosphorylated Cdc25C (both endogenous and exogenous, not shown), and NEBD and CC
(Fig. 3d). Similar to the DNA damage checkpoint-arrested
extracts rescued by Cdc25C(S287A) (Fig. 2c), histone H1
kinase activity levels peaked on entry into M-phase, abruptly dropped
to interphase levels, and then started to increase slowly (Fig.
3a). Again, p42 MAPK was fully activated just after the peak
of histone H1 kinase activity. The fall in histone H1 kinase activity
coincided precisely with proteolysis of Cyclin B2, and then Cyclin B2
began to accumulate as levels of histone H1 kinase activity rose (Fig. 3a).
When PD was added to egg extracts with 700 sperm/µl and
Cdc25C(S287A), entry into M-phase occurred at the same time as in extracts without PD, with a peak of histone H1 kinase activity followed
by a sudden drop to interphase levels (Fig. 3, a and b). In these PD-treated extracts, Cyclin B2 was proteolyzed,
and then Cyclin B2 accumulated later than in extracts without PD (Fig. 3b). In contrast, however, p42 MAPK activation was
completely inhibited by PD in these extracts (5), and after entering
M-phase (as determined by the appearance of MPM-2-reactive
phosphoproteins, and NEBD and CC (Fig. 3e)), the extracts
exited M-phase and entered interphase. Transition to interphase was
accompanied by decondensing nuclei (Fig. 3f), disappearance
of M-phase-specific phosphoproteins (Fig. 3b), and
dephosphorylation of Cdc25C (both endogenous and exogenous, not shown).
Taken together, our results show that although the activation of Cyclin
B-Cdc2 complexes is required for entry into M-phase, p42 MAPK
inactivation is required for exit from M-phase and transition to
interphase. Moreover, these results also suggest that although entry
into M-phase is required for the phosphorylation of Cdc25C and other
MPM-2-reactive phosphoproteins, the sustained phosphorylations observed
in M-phase arrest are maintained by p42 MAPK activation.
The major findings of this study are that the activation of p42
MAPK maintains M-phase arrest after the inactivation of MPF by Cyclin B
destruction and that the inactivation of p42 MAPK is necessary for exit
from M-phase. Recently, we have shown that when p42 MAPK is
constitutively activated in cycling Xenopus egg extracts
after the peak of MPF kinase activity, there is brief drop in Cdc2
activity due to Cyclin B (7). These results and those of the present
work are unexpected given that the M-phase arrest in egg extracts
previously observed in response to activators of the p42 MAPK (see
Refs. 4 and 5, and Fig. 1, this study) or induction of the spindle
assembly checkpoint (2, 23) exhibited sustained H1 kinase activity with
stabilized B-type cyclins (2, 4, 23).
There are similarities between the M-phase-arrested extracts as
represented in Fig. 1, and the M-phase-arrested extracts in Figs. 2 and
3 of this study. In all of the extracts, MPF is activated on entry into
M-phase, and M-phase-specific phosphoproteins appear and are sustained.
In addition, nuclei undergo NEBD and CC and remain in this state. By
these criteria alone, it would be reasonable to predict that
maintenance of MPF activity was solely responsible for the M-phase
arrest in all of these extracts. However, the data in Figs. 2 and 3
clearly demonstrate that M-phase can be sustained by p42 MAPK after
Cyclin B proteolysis and the fall of MPF activity to interphase levels,
suggesting that p42 MAPK has additional functions later in M-phase that
can maintain cell cycle arrest.
Differences in the timing of p42 MAPK activation in these extracts may
account for these apparent contradictory findings. When the activation
of p42 MAPK by MEK(QP) occurs during entry into M-phase coincident with
MPF activation, high levels of MPF activity are maintained, and Cyclin
B is stabilized (Fig. 1). In contrast, when interphase extracts are
driven into M-phase by Cdc25(S287A) (Figs. 2 and 3), p42 MAPK is fully
activated after the peak of histone H1 kinase activity, at a time when
MPF activity is rapidly falling. Therefore, in extracts driven into
M-phase by Cdc25C protein addition there appears to be a dissociation between the cycle of MPF activation and inactivation and the timing of
p42 MAPK activation. Under these conditions, p42 MAPK clearly sustained
M-phase even after cyclin destruction. Similarly, in all of our cycling
extracts studied to date (5, 7), the transient activation of p42 MAPK
always occurred after the peak of MPF activity, and nuclei in M-phase
continued to be present (post-cyclin destruction) in all samples that
contained active p42 MAPK. Also, the addition of PD to cycling extracts
shortened the duration of M-phase (judged by cytology) as compared with that observed in untreated cycling extracts (data not shown, see Ref.
10). Together with the results presented here, these observations suggest that the brief transient of p42 MAPK activation in normally cycling extracts can also extend M-phase after the inactivation of MPF
by cyclin destruction.
After proteolysis, Cyclin B2 reappeared sooner in untreated extracts
than in PD-treated extracts, suggesting that the duration of cyclin
destruction in extracts with activated p42 MAPK was shorter than in
extracts with unactivated p42 MAPK. These results are consistent with
the results of previous studies that p42 MAPK activation can prevent
the initiation of cyclin destruction (Fig. 1, this study, and Refs. 2
and 3). Our results further suggest that p42 MAPK activation can also
turn off the destruction pathway once it has been activated (Figs.
2c and 3).
We also observed that histone H1 kinase activity reappears sooner in
untreated extracts than in PD-treated extracts (Fig. 3). One
explanation for this increase in activity could be that Cdc25C (both
endogenous and exogenous) is stabilized in an active state by p42 MAPK
in untreated extracts. As a result, as newly synthesized B-type cyclins
(mitotic cyclins are continuously synthesized throughout the cell
cycle, see Ref. 27) form complexes with Cdc2, these complexes could be
activated immediately due to the activated exogenous and endogenous
Cdc25C. There are two p42 MAPK consensus sites in Cdc25C, and we are
presently exploring the possible role of these sites in the
stabilization of Cdc25C hyperphosphorylation and activity.
Recently, it has been shown that activated MAPKs (p42 and p44) have
been detected at kinetochores and at the periphery of condensed
chromosomes during M-phase in somatic mammalian cells (28, 29). These
results suggest that active p42 MAPK in Xenopus egg extracts
could be similarly localized to chromatin during M-phase in cycling
Xenopus egg extracts and in the Cdc25-induced M-phase-arrested extracts reported here. However, the maintenance of
MPM-2-reactive phosphoproteins in p42 MAPK-arrested extracts suggests
that M-phase conditions are uniform throughout the extract and extend
beyond a simple localized effect on chromatin.
Our results provide strong evidence that although the activation of
MPF-Cyclin B-Cdc2 complexes is required for entry into M-phase, once
established M-phase can be sustained by p42 MAPK activation and does
not require the maintenance of MPF activity. Therefore, whereas the
activation of MPF drives the cell cycle from interphase into M-phase,
it appears that the inactivation of p42 MAPK, in addition to
inactivation of MPF, is required for exit from M-phase.
We thank James Stone for the constitutively
active rat MEK1(Q56P) cDNA and for comments on the manuscript;
Akiko Kumagai and Bill Dunphy for the pET3a-xCdc25-1 construct;
Manfred Lohka for Cyclin B2NT antibodies; Brian Druker for
phosphotyrosine antibodies; and Annissa Wong for technical assistance.
*
This work was supported by a Medical Research Council
Operating Grant and an Alberta Heritage Foundation for Medical Research Establishment grant (to E. K. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
2
A. S-S. Chau and E. K. Shibuya,
unpublished observations.
3
M. J. Lohka, unpublished observations.
The abbreviations used are:
MPF, M-phase
promoting factor;
MAPK, mitogen-activated protein kinase;
PD, PD98059;
MEK, MAPK/extracellular signal-regulated kinase kinase;
CC, chromosome
condensation;
NEBD, nuclear envelope breakdown;
WT, wild type.
Inactivation of p42 Mitogen-activated Protein Kinase Is
Required for Exit from M-phase after Cyclin Destruction*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (95K):
[in a new window]
Fig. 1.
Activation of p42 MAPK on entry into M-phase
arrests the cell cycle with sustained histone H1 kinase activity and
stabilized Cyclin B. Reactions containing cycling egg extracts
were incubated for 40 min, and then either buffer or a constitutively
active MEK protein (MEK(QP)) was added. Samples were taken immediately,
and then every 10 min (') for analysis by immunoblotting, histone H1
kinase assay, and cytology. U is an extract of unfertilized
eggs arrested in M-phase. Bold lines below figures indicate
time points when NEBD, CC, and mitotic microtubules (markers of
M-phase) were observed. a, samples were immunoblotted with
phosphotyrosine antibodies (to detect activated p42 MAPK, upper
panels) and Cyclin B2 antibodies (middle panels).
Samples were also analyzed for histone H1 kinase activity (lower
panels). Arrowhead indicates time point when condensed
chromosomes associated with spindles were first observed. b,
condensed chromosomes associated with spindle microtubules in a sample
taken at 60 min after MEK(QP) addition in a. Left
panel, phase/contrast image; middle panel, fluorescence
image (Hoechst); right panel, fluorescence/phase/contrast
dual exposure. Bar indicates 10 µm. c, samples
from a reaction with buffer addition (left panel) or MEK(QP)
addition at 40 min of incubation (a) were immunoblotted with
MPM-2 antibodies.

View larger version (40K):
[in a new window]
Fig. 2.
A mutant Cdc25C protein drives DNA damage
checkpoint-arrested egg extracts into a sustained M-phase arrest, with
constitutive activation of p42 MAPK. We expressed and purified
from E. coli a mutant Cdc25C protein in which the serine at
position 287 was mutated to an alanine. To test this construct, we
induced the DNA damage checkpoint in egg extracts by UV-irradiating
sperm nuclei prior to addition to reactions at 700 nuclei/µl.
Untreated sperm + buffer (a), UV-irradiated sperm + buffer
(b), or UV-irradiated sperm + Cdc25C(S287A) (c)
was added to reactions, and samples were taken starting at 60 min of
incubation. Samples were immunoblotted with phosphotyrosine antibodies
(upper panels), Cyclin B2 antibodies (second
panels), and MPM-2 antibodies (third panels).
Bold lines below MPM-2 blots indicate time points when NEBD,
CC, and mitotic microtubules were observed. Graphs below
blots show phosphorimage quantitation of histone H1 kinase
assays.

View larger version (60K):
[in a new window]
Fig. 3.
Exit from M-phase arrest induced by
Cdc25C(S287A) is dependent on inactivation of p42 MAPK and not MPF
activity. Sperm nuclei (700 nuclei/µl) were added to egg
extracts with Cdc25C(S287A) protein either without (a) or
with (b) the MEK inhibitor, PD98059 (PD). Samples
were taken starting at 60 min of incubation. Samples were immunoblotted
with phosphotyrosine antibodies (upper panels), Cyclin B2
antibodies (second panels), and MPM-2 antibodies
(third panels). Bold lines below MPM-2 blots
indicate time points when NEBD, CC, and mitotic microtubules were
observed. Graphs below blots show phosphorimage quantitation
of histone H1 kinase assays. c
f, fluorescence images
(Hoechst); bar = 10 µm. c, decondensed
nucleus in sample taken at 60 min from reaction in a
(shaded arrowhead). d, condensed chromosomes in
sample taken at 180 min from reaction in a (solid
arrowhead). e, condensed chromosomes in sample taken at
90 min from reaction in b (solid arrowhead).
f, decondensed nucleus in sample taken at 120 min from
reaction in b (shaded arrowhead).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Scholar of the Medical Research Council and the Alberta Heritage
Foundation for Medical Research. To whom correspondence should be
addressed: Dept. of Cell Biology, University of Alberta, 6-30 Medical
Sciences Bldg., Edmonton, Alberta T6G 2H7, Canada. Tel.: 780-492-1804;
Fax: 780-492-0450; E-mail: eshibuya@anat.med.ualberta.ca.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Wells, W. A.
(1996)
Trends Cell Biol.
6,
228-234
2.
Minshull, J.,
Sun, H.,
Tonks, N. K.,
and Murray, A. W.
(1994)
Cell
79,
475-486[CrossRef][Medline]
[Order article via Infotrieve]
3.
Abrieu, A.,
Lorca, T.,
Labbe, J. C.,
Morin, N.,
Keyse, S.,
and Doree, M.
(1996)
J. Cell Sci.
109,
239-246[Abstract]
4.
Walter, S. A.,
Guadagno, T. M.,
and Ferrell, J. E., Jr.
(1997)
Mol. Biol. Cell
8,
2157-2169 5.
Bitangcol, J. C.,
Chau, A. S.-S.,
Stadnick, E.,
Dicken, B.,
Lohka, M. J.,
and Shibuya, E. K.
(1998)
Mol. Biol. Cell
9,
451-467 6.
Abrieu, A.,
Fisher, D.,
Simon, M.-N.,
Doree, M.,
and Picard, A.
(1997)
EMBO J.
16,
6407-6413[CrossRef][Medline]
[Order article via Infotrieve]
7.
Chau, A. S.-S.,
and Shibuya, E. K.
(1998)
Biol. Cell
90,
565-572[CrossRef][Medline]
[Order article via Infotrieve]
8.
Izumi, T.,
Walker, D. H.,
and Maller, J. L.
(1992)
Mol. Biol. Cell
3,
927-939[Abstract]
9.
Kumagai, A.,
and Dunphy, W. G.
(1992)
Cell
70,
139-151[CrossRef][Medline]
[Order article via Infotrieve]
10.
Walter, S. A.,
Guadagno, T. M.,
and Ferrell, J. E., Jr.
(1997)
Mol. Biol. Cell
8,
2157-2169
11.
Kumagai, A.,
Yakowec, P. S.,
and Dunphy, W. G.
(1998)
Mol. Biol. Cell
9,
345-354 12.
Kumagai, A.,
Guo, Z.,
Emami, K. H.,
Wang, S. X.,
and Dunphy, W. G.
(1998)
J. Cell Biol.
142,
1559-1569 13.
Murray, A. W.,
and Kirschner, M. W.
(1989)
Nature
339,
275-280[CrossRef][Medline]
[Order article via Infotrieve]
14.
Vigers, G. P.,
and Lohka, M. J.
(1991)
J. Cell Biol.
112,
545-556 15.
Peng, C. Y.,
Graves, P. R.,
Thoma, R. S.,
Wu, Z.,
Shaw, A. S.,
and Piwnica-Worms, H.
(1997)
Science
277,
1501-1505 16.
Sanchez, Y.,
Wong, C.,
Thoma, R. S.,
Richman, R.,
Wu, Z.,
Piwnica-Worms, H.,
and Elledge, S. J.
(1997)
Science
277,
1497-1501 17.
Alessi, D. R.,
Cuenda, A.,
Cohen, P.,
Dudley, D. T.,
and Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
27489-27494 18.
Druker, B. J.,
Manon, H. J.,
and Roberts, T. M.
(1989)
N. Eng. J. Med.
321,
1383-1389[Medline]
[Order article via Infotrieve]
19.
van der Velden, H. M. W.,
and Lohka, M. J.
(1993)
Mol. Cell. Biol.
13,
1480-1488 20.
Shibuya, E. K.,
Boulton, T. G.,
Cobb, M. H.,
and Ruderman, J. V.
(1992)
EMBO J.
11,
3963-3975[Medline]
[Order article via Infotrieve]
21.
Shibuya, E. K.,
and Ruderman, J. V.
(1993)
Mol. Biol. Cell
3,
781-790
22.
Bottorff, D.,
Stang, S.,
Agellon, S.,
and Stone, J. C.
(1995)
Mol. Cell. Biol.
5,
5113-5122
23.
Takenaka, K.,
Gotoh, Y.,
and Nishida, E.
(1997)
J. Cell Biol.
136,
1091-1097 24.
Davis, F. M.,
Tsao, T. Y.,
Fowler, S. K.,
and Rao, P. N.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
2926-2930 25.
Dasso, M.,
and Newport, J. W.
(1990)
Cell
61,
811-823[CrossRef][Medline]
[Order article via Infotrieve]
26.
Coleman, T. R.,
and Dunphy, W. G.
(1994)
Curr. Opin. Cell Biol.
6,
877-882[CrossRef][Medline]
[Order article via Infotrieve]
27.
Evans, T.,
Rosenthal, E. T.,
Youngbloom, J.,
Distel, D.,
and Hunt, T.
(1983)
Cell
33,
389-396[CrossRef][Medline]
[Order article via Infotrieve]
28.
Shapiro, P. S.,
Vaisberg, E.,
Hunt, A. J.,
Tolwinski, N. S.,
Whalen, A. M.,
McIntosh, J. R.,
and Ahn, N. G.
(1998)
J. Cell Biol.
142,
1533-1545 29.
Zecevic, M.,
Catling, A. D.,
Eblen, S. T.,
Renzi, L.,
Hittle, J. C.,
Yen, T. J.,
Gorbsky, G. J.,
and Weber, M. J.
(1998)
J. Cell Biol.
142,
1547-1558
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. Nika, C. Charvet, S. Williams, L. Tautz, S. Bruckner, S. Rahmouni, N. Bottini, S. P. Schoenberger, G. Baier, A. Altman, et al. Lipid Raft Targeting of Hematopoietic Protein Tyrosine Phosphatase by Protein Kinase C {theta}-Mediated Phosphorylation. Mol. Cell. Biol., March 1, 2006; 26(5): 1806 - 1816. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Stanford and J. V. Ruderman Changes in Regulatory Phosphorylation of Cdc25C Ser287 and Wee1 Ser549 during Normal Cell Cycle Progression and Checkpoint Arrests Mol. Biol. Cell, December 1, 2005; 16(12): 5749 - 5760. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kiss-Toth, S. M. Bagstaff, H. Y. Sung, V. Jozsa, C. Dempsey, J. C. Caunt, K. M. Oxley, D. H. Wyllie, T. Polgar, M. Harte, et al. Human Tribbles, a Protein Family Controlling Mitogen-activated Protein Kinase Cascades J. Biol. Chem., October 8, 2004; 279(41): 42703 - 42708. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Detivaud, G. Pascreau, A. Karaiskou, H. B. Osborne, and J. Z. Kubiak Regulation of EDEN-dependent deadenylation of Aurora A/Eg2-derived mRNA via phosphorylation and dephosphorylation in Xenopus laevis egg extracts J. Cell Sci., July 1, 2003; 116(13): 2697 - 2705. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lin and H. Zhang Mitogen-Activated Protein Kinase in Pfiesteria piscicida and Its Growth Rate-Related Expression Appl. Envir. Microbiol., January 1, 2003; 69(1): 343 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Su, D. H. Parry, B. Donahoe, C.-T. Chien, P. H. O'Farrell, and A. Purdy Cell cycle roles for two 14-3-3 proteins during Drosophila development J. Cell Sci., January 10, 2001; 114(19): 3445 - 3454. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Walter, S. N. Guadagno, and J. E. Ferrell Jr. Activation of Wee1 by p42 MAPK In Vitro and in Cycling Xenopus Egg Extracts Mol. Biol. Cell, March 1, 2000; 11(3): 887 - 896. [Abstract] [Full Text] |
||||
![]() |
C. Hayne, G. Tzivion, and Z. Luo Raf-1/MEK/MAPK Pathway Is Necessary for the G2/M Transition Induced by Nocodazole J. Biol. Chem., October 6, 2000; 275(41): 31876 - 31882. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |